A Trial to Learn if Having ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
Conditions:   Nonalcoholic Steatohepatitis;   Genetic Risk Factor Interventions:   Drug: ALN-PNP Dose Level 1;   Drug: ALN-PNP Dose Level 2;   Drug: ALN-PNP Dose Level 3;   Drug: Matching Placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 6, 2023 Category: Research Source Type: clinical trials